CSL Receives FDA Approval for ANDEMBRY Treatment

CSL, an Australian biotech firm, has received FDA approval for its ANDEMBRY treatment, a therapy for patients aged 12 and above with hereditary angioedema (HAE).

The FDA approval marks a significant development in the field of HAE prophylaxis.

Key Financial Metrics:

• CSL’s stock price has fluctuated between 228.61 AUD and 313.25 AUD over the past year.
• Current stock price: 238.86 AUD
• Price-to-earnings ratio: 29.4742
• Price-to-book ratio: 4.37058

These metrics provide a snapshot of the company’s valuation and financial performance.